The mechanism of solifenacin release from a pH-responsive ion-complex oral suspension in the fasted upper gastrointestinal lumen.


Journal

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
ISSN: 1879-0720
Titre abrégé: Eur J Pharm Sci
Pays: Netherlands
ID NLM: 9317982

Informations de publication

Date de publication:
15 Jan 2020
Historique:
received: 14 08 2019
revised: 09 10 2019
accepted: 10 10 2019
pubmed: 2 11 2019
medline: 2 6 2020
entrez: 1 11 2019
Statut: ppublish

Résumé

The main objective of this study was to investigate the mechanism of solifenacin release from a pH-responsive ion-complex oral resinate suspension under conditions simulating the environment in the upper gastrointestinal lumen. A secondary objective was to propose an appropriate in vitro methodology for evaluating the quality of orally administered solifenacin suspensions. The mechanism of solifenacin release from polacrilin potassium resin (Amberlite® IRP88) was investigated using biorelevant media and compendial setups (USP Apparatus 2 and USP Apparatus 4) and using newer, recently validated in vitro methodologies [biorelevant gastrointestinal transfer (BioGIT) system]. We evaluated the impact of particle size and concentration of the resin; thickener concentration (carbomer homopolymer, type B); and the impact of pH, cationic strength, agitation intensity and level of simulation of contents in the upper gastrointestinal lumen. Data suggested that solifenacin release from the resinate was determined by the resin particle size, the medium pH, cationic strength (when the conditions in the upper small intestine are simulated) and the level of simulation of contents in the upper small intestine. The interaction of solifenacin with taurocholic acid/lecithin aggregates was significant, but unlikely to affect the degree of solifenacin absorption, as a BCS Class I compound. Under acidic conditions, solifenacin was dissociated and released from the pH-responsive resin rapidly. Under conditions simulating the contents of the upper small intestine, solifenacin was replaced by cations from the testing media and diffused through the resin matrix. All three in vitro systems with or without a pH gradient are useful in distinguishing solifenacin release characteristics from resinate suspensions with different particle sizes. Because of this drug release mechanism, USP Apparatus 2 with fixed pH media demonstrated equivalent or slightly higher discriminative sensitivity than the other setups and appears to be appropriate for product quality control.

Identifiants

pubmed: 31669386
pii: S0928-0987(19)30380-X
doi: 10.1016/j.ejps.2019.105107
pii:
doi:

Substances chimiques

Suspensions 0
Solifenacin Succinate KKA5DLD701

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105107

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Yosuke Yamamoto (Y)

Analytical Research Laboratories, Astellas Pharma Inc., 180 Ozumi, Yaizu, Yaizu, Shizuoka 425-0072, Japan.

Harumi Kumagai (H)

Analytical Research Laboratories, Astellas Pharma Inc., 180 Ozumi, Yaizu, Yaizu, Shizuoka 425-0072, Japan.

Moe Haneda (M)

Analytical Research Laboratories, Astellas Pharma Inc., 180 Ozumi, Yaizu, Yaizu, Shizuoka 425-0072, Japan.

Maria Vertzoni (M)

Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, 157 84, Zografou, Greece.

Niels Ouwerkerk (N)

European Analytical Research Laboratories, Astellas Pharma Europe B.V., Leiden, Leiden 2333 BE, the Netherlands.

Daisuke Murayama (D)

Analytical Research Laboratories, Astellas Pharma Inc., 180 Ozumi, Yaizu, Yaizu, Shizuoka 425-0072, Japan.

Yoshifumi Katakawa (Y)

Analytical Research Laboratories, Astellas Pharma Inc., 180 Ozumi, Yaizu, Yaizu, Shizuoka 425-0072, Japan.

Kei Motonaga (K)

Analytical Research Laboratories, Astellas Pharma Inc., 180 Ozumi, Yaizu, Yaizu, Shizuoka 425-0072, Japan.

Christos Reppas (C)

Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis, 157 84, Zografou, Greece.

Tomokazu Tajiri (T)

Analytical Research Laboratories, Astellas Pharma Inc., 180 Ozumi, Yaizu, Yaizu, Shizuoka 425-0072, Japan. Electronic address: tomokazu.tajiri@astellas.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH